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See page 661 for the editorial comment on this article (doi: 10.1093/eurheartj/ehw626)
Aims Cardiopoietic cells, produced through cardiogenic conditioning of patients’ mesenchymal stem cells, have shown
preliminary efficacy. The Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) trial aimed to
validate cardiopoiesis-based biotherapy in a larger heart failure cohort.
...................................................................................................................................................................................................
Methods
and results
This multinational, randomized, double-blind, sham-controlled study was conducted in 39 hospitals. Patients with symp-
tomatic ischaemic heart failure on guideline-directed therapy (n= 484) were screened; n= 348 underwent bone mar-
row harvest and mesenchymal stem cell expansion. Those achieving > 24 million mesenchymal stem cells (n= 315)
were randomized to cardiopoietic cells delivered endomyocardially with a retention-enhanced catheter (n= 157) or
sham procedure (n= 158). Procedures were performed as randomized in 271 patients (n= 120 cardiopoietic cells,
n= 151 sham). The primary efficacy endpoint was a Finkelstein–Schoenfeld hierarchical composite (all-cause mortality,
worsening heart failure, Minnesota Living with Heart Failure Questionnaire score, 6-min walk distance, left ventricular
end-systolic volume, and ejection fraction) at 39 weeks. The primary outcome was neutral (Mann–Whitney estimator
0.54, 95% confidence interval [CI] 0.47–0.61 [value > 0.5 favours cell treatment], P = 0.27). Exploratory analyses sug-
gested a benefit of cell treatment on the primary composite in patients with baseline left ventricular end-diastolic vol-
ume 200–370 mL (60% of patients) (Mann–Whitney estimator 0.61, 95% CI 0.52–0.70, P = 0.015). No difference was
observed in serious adverse events. One (0.9%) cardiopoietic cell patient and 9 (5.4%) sham patients experienced
aborted or sudden cardiac death.
...................................................................................................................................................................................................
Conclusion The primary endpoint was neutral, with safety demonstrated across the cohort. Further evaluation of cardiopoietic
cell therapy in patients with elevated end-diastolic volume is warranted.
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Introduction
Heart failure is a leading cause of mortality and morbidity; it limits
quality of life and imposes a major societal burden.1 Ischaemic heart
disease underpins two-thirds of all systolic heart failure.2 Extensive
myocardial remodelling and chamber enlargement portend poor
outcomes, and standard treatments are often insufficient in such pa-
tients.3 Cardiac transplantation or destination mechanical circulatory
support remains high-risk therapeutic options that are further limited
by donor availability, patient eligibility, and cost.4
By targeting myocardial restoration, cell-based therapies are alleged
paradigm-shifting alternatives.5,6 Clinical trials document reassuring
feasibility and safety yet inconsistent efficacy, ascribed in part to unpre-
dictable potency of cell products and limited retention.7,8 These short-
comings impede advancement into cardiovascular practice.
Strategies for cell therapy optimization9 include myocardial priming
to improve cell homing,10 exploiting resident cell populations11 or lev-
eraging combined cell regimens.12,13 Guided cardiopoiesis is a recent
option that enhances the cardioreparative functionality of patient-
derived mesenchymal stem cells (MSC) and induces a restorative re-
sponse in failing hearts.14 The cardiopoietic phenotype demonstrated
promise in proof-of-concept studies15 and in the Cardiopoietic Stem
Cell Therapy in Heart Failure (C-CURE) clinical trial.16
The Congestive Heart Failure Cardiopoietic Regenerative Therapy
(CHART-1) trial was executed to validate the efficacy and safety of
cardiopoietic cells delivered via an enhanced retention performance
catheter17 in a larger population with advanced symptomatic heart
failure of ischaemic aetiology.18
Methods
Study design
The CHART-1 study is a prospective, multicentre, randomized, sham-
controlled, patient- and evaluator-blinded clinical trial. Investigators at 39
centres in Europe and Israel participated (Figure 1 and Supplementary material
online, Section 1). Ethics committee approvals were obtained for each partici-
pating centre. The CHART-1 trial was registered with clinicaltrials.gov
(NCT01768702) and EudraCT (2011-001117-13). The study design has previ-
ously been described,18 and the study protocol is provided in Supplement 2.
Patients
Eligible patients gave written informed consent prior to any study-related
procedures. Patients were not compensated for participation except for
travel expenses. Patients were >_ 18 to < 80 years old with left ventricular
ejection fraction (LVEF) <_ 35% (locally interpreted echocardiograms were
used for screening), ischaemic heart failure without need for revasculariza-
tion, heart failure hospitalization, or outpatient vasoactive heart failure ther-
apy (e.g. vasodilators, positive inotropic agents, vasopressors or diuretics)
within 12 months, in New York Heart Association (NYHA) class II or
greater at screening, and with NYHA class III or IV or Interagency Registry
for Mechanically Assisted Circulatory Support (INTERMACS) class >_ 4
within 12 months.18 Guideline-directed medical therapy, a 6-min walk dis-
tance > 100 to <_400 m and Minnesota Living with Heart Failure
Questionnaire (MLHFQ) score > 30 were required. Acute coronary syn-
drome or percutaneous coronary intervention within 90 days, or coronary
artery bypass graft surgery within 180 days were exclusions.18 Eligible pa-
tients were scheduled for bone marrow harvest and MSC expansion.
Approximately 2 weeks after screening, bone marrow (65–85 mL)
was collected from the iliac crest and shipped to a central production
Cardiopoietic cell therapy for advanced ischaemic heart failure 649
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facility (Celyad, Mont-Saint-Guibert, Belgium). If the bone marrow was of
insufficient quantity, contaminated, or did not reach pre-specified cell
production criteria, the harvest could be repeated. Patients with a second
inadequate cell expansion or those who refused a second bone marrow
harvest were discontinued from further participation.
Randomization and masking
Patients were randomized 1:1 to cardiopoietic cell injection or a sham
control procedure after confirmation by the central production facility
that > 24 million MSCs were achieved according to pre-specified release
criteria. An Interactive Web Randomization Service was used according
to a central randomization scheme (produced by Harvard Clinical
Research Institute, Boston, Massachusetts) stratified by study centre with
random permuted blocks within each centre. Patients and evaluators
were blinded to study group assignment (eMethods in Supplementary ma
terial online, Section 2.1).
Procedures
MSCs for patients randomized to active treatment were processed for
lineage specification to derive cardiopoietic cells (eMethods in
Figure 1 Consolidated standards of reporting trials diagram of the CHART-1 study. This figure depicts the patient flow through the trial. Eighteen
(11.5%) patients randomized to active treatment and 7 (4.4%) patients randomized to control did not undergo the study procedure: 10 (6.4%) and 6
(3.8%) patients died, and 2 (1.3%) and 1 (0.6%) patients withdrew consent in the active and control groups, respectively. Six (3.8%) patients random-
ized to active treatment were discontinued because of procedural contraindications including left ventricular thrombus and aortic stenosis not identi-
fied at screening. Cell release specifications were not achieved in 18 (11.5%) patients randomized to active treatment; these patients and one
additional patient for whom the injection procedure was deemed unsafe underwent a sham procedure and were followed separately. The remaining
120 patients underwent injection of cardiopoietic cells.
aOther reasons patients were withdrawn after screening but before bone marrow harvest included: withdrawal from the study by investigator or
sponsor; patient missing or lost to follow-up; or other miscellaneous.
bForty-eight (13.8%) patients who failed the first bone marrow harvest (1 due to inadequate sample volume, 8 due to improper harvesting or trans-
port process, 21 because the sample was contaminated, and 18 because of inadequate expansion of MSCs) were eligible for a repeat harvest. Thirty-
two patients underwent the second bone marrow harvest. Of the 16 who did not have a repeat, 5 were because the patient refused, 2 were due to
SAEs (1 patient had a stroke and another was hospitalized for heart failure), and the rest for sponsor reason (either cell-process related or because
study enrollment was nearing completion).
cOther reasons patients were withdrawn after bone marrow harvest but before randomization included: withdrawal from the study by sponsor or
other miscellaneous.
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Supplementary material online, Section 2.2).16 Patients whose cell prod-
uct did not meet release criteria because of inadequate identity, potency,
content, purity, homogeneity, or microbiological content (eMethods in
Supplementary material online, Section 2.2.2) received a sham procedure
(Figure 1). Cryopreserved cardiopoietic cell batches meeting release cri-
teria (C3BS-CQR-1 manufactured by Celyad, Mont-Saint-Guibert,
Belgium) were shipped frozen to sites and reconstituted within 6 h before
injection. Cardiopoietic cells were delivered using standard cardiac cath-
eterization procedures and a cell retention-enhanced injection catheter
(C-Cathez
TM; Celyad, Mont-Saint-Guibert, Belgium).17 Intramyocardial in-
jections (0.5 mL each,1 cm apart) were made into left ventricle areas
with wall thickness >_ 8 mm, avoiding the apex and segments adjacent to
the mitral or aortic valves. Target zones were mapped using biplane left
ventricular angiography integrating preceding echocardiography informa-
tion regarding wall thickness. A sham procedure, incorporating insertion
of an introducer sheath, left ventricular angiography and pigtail catheter
movements, was performed for patients randomized to the control
group and in the patients whose cell product did not meet pre-specified
release criteria.
Follow-up visits were conducted by the blinded investigator team.18
Pre-procedure (baseline), 26 and 39-week echocardiograms were as-
sessed centrally by a blinded core laboratory (eMethods in
Supplementary material 1 online, Section 2.3).
Outcomes
The primary efficacy outcome was a hierarchical composite assessed at 39
weeks post-procedure comprising all-cause mortality (days to death), the
number of worsening heart failure events (0, 1, or >_ 2), MLHFQ score (>_
10 point improvement, >_ 10 point deterioration, or no meaningful
change), 6-min walk distance (>_ 40 m improvement, >_ 40 m deterioration,
or no meaningful change), left ventricular end-systolic volume (LVESV)
change (>_ 15 mL improvement, >_ 15 mL deterioration, or no meaningful
change), and LVEF change (>_ 4% absolute improvement, >_ 4% absolute
deterioration, or no meaningful change as assessed by the echocardio-
graphic core laboratory).18 Left ventricular assist device (LVAD) implant-
ation or urgent heart transplantation was considered cardiac deaths for
the efficacy analyses.
Safety assessment through Week 39 included all-cause mortality,
rehospitalization, cardiac transplantation, myocardial infarction, stroke,
aborted sudden death (resuscitated sudden death or appropriate
implantable cardioverter defibrillator [ICD] shocks), and serious and
non-serious adverse events.
Statistical analysis
The primary outcome was compared between groups using a
Finkelstein-Schoenfeld approach,19 which allows mortality and morbidity
components to be combined with other important aspects of the heart
failure disease process in one outcome. Patients are ranked with respect
to their clinical outcomes through comparing every patient to every
other patient on the hierarchy of component outcomes ordered by their
relative importance19 (eMethods in Supplementary material online,
Section 2.4, eFigure 1 in Supplementary material online, Section 2.4.1).
Missing data are accommodated in the algorithm, with limited need for
imputation (eMethods in Supplementary material online, Section 2.4;
Supplement material 2 [protocol], page 40). The primary analysis was
performed in patients as randomized, excluding patients whose cell prod-
uct did not meet release criteria. Sensitivity analyses were performed in a
modified intention-to-treat set including all patients who underwent the
study procedure, and a per-protocol set excluding patients with major
protocol deviations. All analyses were conducted using a two-sided sig-
nificance level of 0.05.
A sample size of 120 patients per group was estimated to provide 87%
power to detect a treatment effect corresponding to a Mann–Whitney
estimator (the probability of a better response in the active treatment
group plus half the probability of a tie) of 0.61 (values > 0.5 favour active
treatment).18 This treatment effect corresponds to a Mann–Whitney
odds of 1.56, the relative probability of a better outcome on active treat-
ment than on control. Homogeneity of the treatment effect across sub-
groups was assessed using chi-square tests computed from Mann–
Whitney estimators and their corresponding variances in the subgroups.
Post-hoc subgroup analyses evaluated treatment effect by baseline sever-
ity markers including left ventricular end-diastolic volume (LVEDV), left
ventricular end-systolic volume (LVESV), MLHFQ score, 6-min walk dis-
tance, and LVEF. Subpopulation Treatment Effect Pattern Plots (STEPPs)
were used to evaluate the potential effect of treatment by baseline sever-
ity markers.20
Safety analyses included all patients according to the treatment
received. Kaplan–Meier estimates of event rates through Week 39 and
hazard ratios and 95% confidence intervals (CI) from Cox regression
models are presented; groups were compared using log-rank tests.
Means± standard deviation (SD) or median, and interquartile range
(IQR), are presented for continuous variables, and geometric mean and
95% CI for log-transformed variables. Analyses are based on the data
when the last patient to have a study procedure reached Week 39. SASVR
(Cary, North Carolina, USA) version 9.3 was used for analyses.
A blinded Clinical Events Committee (CEC) adjudicated all deaths,
worsening heart failure events, strokes, myocardial infarctions, and
aborted sudden deaths from randomization (eMethods in Supplementary
material online, Section 2.3). An independent interventional cardiologist
adjudicated the relatedness of peri-procedural serious adverse events to
the injection catheter, the catheterization procedure, and the cardio-
poietic cell product. An independent Data Safety Monitoring Board
(DSMB) reviewed ongoing safety reports, evaluated safety of the delivery
device when the first 46 patients had 4 weeks follow-up, and reviewed
safety data and a futility analysis when 120 patients had at least 13 weeks
follow-up (eMethods in Supplementary material online, Section 2.3).
Results
Study population
Screening began 18 December 2012 and the last injection procedure
(cardiopoietic cell therapy or sham) was performed 31 July 2015. A
total of 484 patients provided informed consent to undergo eligibility
screening, and 348 underwent bone marrow harvest (Figure 1).
Adequate MSC expansion was achieved in 315 patients, and they
were randomized to cardiopoietic cell therapy (n= 157) or sham
control procedure (n= 158). Of these, 120 patients underwent injec-
tion of cardiopoietic cells and 151 had the sham procedure (Figure 1).
Baseline characteristics were well-balanced between the groups
(Table 1). The mean ± SD age was 61.9± 8.6 years, 89.7% were men,
and all were white. Eighty-five percent of patients had been hospital-
ized for heart failure within the previous year, and 21.8% were in
NYHA Class II at screening. The mean± SD centrally-assessed LVEF
was 27.9± 7.0%. Patients were well-treated with guideline-directed
medical and device therapy (Table 1) that remained consistent during
follow-up (eFigure 2 in Supplementary material online, Section 3.1).
The mean ± SD time between randomization and the study pro-
cedure was 59.8 ± 21.6 and 53.9 ± 11.7 days in patients randomized
to and who received the active treatment vs. the sham procedure,
Cardiopoietic cell therapy for advanced ischaemic heart failure 651
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respectively. The median duration was 112.0 (IQR 78.0–157.5) mi-
nutes for the injection procedure and 36.0 (IQR 17.0–66.0) minutes
for the sham procedure. The treatment group received a median of
19 (IQR 17–20) injections with a median injection volume of 9.6
(IQR 8.5–10) mL.
.................................................................................................
Table 1 Baseline characteristics
Cardiopoietic
cell treatment
Sham control
n5 120 n5 151
Demographics
Male sex 107 (89.2) 136 (90.1)
Age (years) 61.6 (8.6) 62.1 (8.7)
Caucasian race 120 (100) 151 (100)
BMI (kg/m2) 28.2 (3.7) 28.6 (4.4)
Heart Failure History
NYHA class at screening
I 0 0
II 23 (19.2) 36 (23.8)
III 96 (80) 114 (75.5)
IV 1 (0.8) 1 (0.7)
Time from first heart
failure diagnosis to
screening (months)
44.1 (12.3–100.1) 46.3 (16–97.7)
Heart failure
hospitalization
within 12 months
102 (85.0) 128 (84.8)
Number of heart failure
hospitalizations in
past 12 months
1.3 (0.8) 1.2 (0.5)
Comorbidities
Chronic angina 38 (31.7) 56 (37.1)
CCSC-I 14 (11.7) 12 (7.9)
CCSC-II 20 (16.7) 36 (23.8)
CCSC-III 4 (3.3) 7 (4.6)
CCSC-IV 0 0
Percutaneous coronary
intervention
98 (81.7) 103 (68.2)
Coronary artery
bypass surgery
32 (26.7) 44 (29.1)
Myocardial infarction 106 (88.3) 133 (88.1)
Cerebrovascular
atherosclerotic disease
13 (10.8) 13 (8.6)
Peripheral vascular disease 5 (4.2) 10 (6.6)
Atrial fibrillation 31 (25.8) 32 (21.2)
Atrial flutter 4 (3.3) 5 (3.3)
Sustained ventricular
tachycardia
12 (10.0) 25 (16.6)
Ventricular fibrillation 10 (8.3) 20 (13.2)
ICD/AICD 46 (38.3) 63 (41.7)
CRT 25 (20.8) 25 (16.6)
Transplant list 1 (0.8) 0
Diabetes mellitus 45 (37.5) 71 (47)
Current smoking 12 (10) 25 (16.6)
Current alcohol abuse 4 (3.3) 7 (4.6)
Hypertension 99 (82.5) 124 (82.1)
Hypercholesterolemia 97 (80.8) 129 (85.4)
Renal impairment 25 (20.8) 36 (23.8)
Chronic lung disease 15 (12.5) 19 (12.6)
Continued
.................................................................................................
Table 1 Continued
Cardiopoietic
cell treatment
Sham control
n5 120 n5 151
Baseline Therapies
Baseline concomitant medications
ACE inhibitor 96 (80) 117 (77.6)
ARB 14 (11.7) 21 (13.9)
ACE inhibitor
or ARB
109 (90.8) 137 (90.7)
Beta blocker 107 (89.2) 135 (89.4)
CCB 6 (5) 27 (17.9)
Alpha blocker 36 (30) 39 (25.8)
MRA 94 (78.3) 109 (77.2)
Loop diuretic 104 (86.7) 123 (81.5)
Statin 107 (89.2) 125 (82.8)
Aspirin 76 (63.3) 100 (66.2)
Vitamin K antagonist 42 (35.0) 60 (39.7)
Baseline Vital Signs, Left Ventricular Parameters, and Biomarkers
HR (bpm) 70.9 (12.5) 70.8 (10.3)
SBP (mmHg) 117 (14.4) 122.6 (15.3)
DBP (mmHg) 72.6 (8.5) 74.2 (10.3)
MLHFQ total score 48.8 (39.8–64.8) 46.5 (37–60)
6-min walk distance
(meters)
332.5 (282–366.8) 332.5 (282.5–367.0)
LVESV (mL) 172.6 (140.4–224.2) 177.9 (133.3–212.4)
LVEF (%) 27 (23–32) 28 (24–32)
LVEDV (mL) 239.9 (197.4–294) 246.4 (198.2–285.6)
NT-proBNP (pg/mL) 1083.1 (450–2648.1) 1077.6 (483.7–2260.6)
SCr (mmol/L) 102.5 (85–128.6) 103 (86–128)
BUN (mmol/L) 7.6 (5.9–10.5) 7.5 (5.5–10.7)
eGFR (mL/min/1.73m2) 60 (52–74.2) 60 (52–78)
Data are expressed as number (percent), mean (standard deviation), or median
(interquartile range). There were no significant differences in baseline characteris-
tics between groups (P> 0.05), except for history of percutaneous coronary
intervention, calcium channel blocker use, and systolic blood pressure (P< 0.05).
ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker; BMI,
body mass index; bpm, beats per minute; BUN, blood urea nitrogen; CCB, cal-
cium channel blocker; CCSC, Canadian Cardiovascular Society Classification;
CRT-D, cardiac resynchronization therapy with defibrillator; CRT-P, cardiac
resynchronization therapy with pacemaker; DBP, diastolic blood pressure; eGFR,
estimated glomerular filtration rate; HR, heart rate; ICD, automatic implantable
cardioverter defibrillator; LVEDV, left ventricular end-diastolic volume; LVEF, left
ventricular ejection fraction; LVESV, left ventricular end-systolic volume; MLHFQ,
Minnesota Living with Heart Failure Questionnaire; MRA, mineralocorticoid re-
ceptor antagonist; NT-proBNP, N-terminal pro brain natriuretic peptide; NYHA,
New York Heart Association; SBP, systolic blood pressure; SCr, serum
creatinine.
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Primary end-point
The hierarchical composite primary endpoint across the total study
cohort was neutral (Mann–Whitney estimator 0.54, 95% CI 0.47–
0.61, P = 0.27) (Figure 2, panel A, eTable 1 in Supplementary material
online, Section 2.4.2), corresponding to a Mann–Whitney odds of
1.17 (95% CI 0.89–1.55). No significant between-group differences
were noted for individual components of the primary outcome, but a
signal for a benefit was observed across the categories of change in 6-
min walk distance (P= 0.07) (Table 2).
Subgroup analysis
The response was similar according to sex (homogeneity P = 0.43),
age (homogeneity P = 0.25), NYHA class (homogeneity P = 0.69),
and geographic region (homogeneity P = 0.71). The effect of active
treatment according to baseline heart failure severity was examined
in post-hoc, exploratory analyses. A suggestion of efficacy for the ac-
tive treatment was noted in patients with LVEDV, LVESV, or MLHFQ
score greater than the median, and in those with 6-min walk distance
less than the median (Figure 3). Subpopulation treatment effect pat-
tern plots were used to further explore the pattern of treatment ef-
fect on the composite primary endpoint as a function of increasing,
overlapping intervals of severity markers. The observed response
patterns are shown in Figure 4. Patients with baseline LVEDV 200–
370 mL receiving cardiopoietic cell treatment had a greater probabil-
ity of a better outcome on the composite primary endpoint com-
pared to the sham control group (Mann–Whitney estimator 0.61,
95% CI 0.52–0.70, P = 0.015; Mann–Whitney odds 1.57, 95% CI
1.09–2.35) (Figure 2, panel B). Patients with baseline LVEDV 200–
370 mL (cardiopoietic cell therapy n= 66, sham control n= 96)
treated with cardiopoietic cell therapy had a greater improvement in
MLHFQ score from baseline that was of nominal significance. A
greater absolute proportion had improvement in 6-min walk distance
compared to sham control, and the absolute proportion with LVESV
improvement was greater and with deterioration lesser in the active
treatment vs. the sham control group, but these differences were not
significant (Table 2). All components of the composite, including all-
cause mortality and worsening heart failure events, were directionally
consistent (Table 2).
Safety
Of the 120 patients undergoing study injections, 106 were without in-
cident and 14 experienced catheter-procedure related serious ad-
verse events. Of the 14 patients, each developed one of the
following: ventricular tachyarrhythmia (4 sustained, responsive to
cardioversion), left bundle branch block (3 sustained, 2 receiving car-
diac resynchronization therapy [CRT] for persistent heart failure 2
and 4.5 months after injection, respectively), dissection of the ascend-
ing aorta requiring surgery (in a patient with known calcific and
dilated thoracic aorta, occurring prior to the procedure while cath-
eter was introduced), transient ischaemic attack (1 with aphasia; nor-
mal head computerized tomography [CT] scan and resolution by
48 h), femoral artery stenosis (1 with claudication; sub-total occlusion
at site of closure device implantation, managed medically), and peri-
cardial effusion (4, three with tamponade responsive to drainage, 1
without hemodynamic consequences resolving spontaneously). No
cases of pericardial tamponade occurred in the final 72 active cases
after additional procedural training and oversight.
Cardiac markers (CK-MB and high-sensitivity cardiac troponin T
[hs-cTnT]) were increased at 6 and 24 h following the cell injection
procedure. At 6 h, CK-MB had increased a median of 3.35 (IQR
-0.600–59.800) mg/L in the active treatment group, compared to a
median change of -0.20 (IQR -11.200–8.800) mg/L in the control
group. At 24 h, median changes were 0.90 (IQR 0.1–1.8) and -0.30
(IQR -0.80–0.00) mg/L in patients treated with active and sham con-
trol, respectively, a ratio of 2.08 (P < 0.001). The median change in
hs-cTnT at 6 h was 0.088 (IQR 0.04–0.151) mg/L in the cardiopoietic
cell treatment group and 0.001 (IQR -0.002–0.003) mg/L in the sham
control. At 24 h, the median change from baseline was 0.059 and
Figure 2 Primary efficacy outcome. Panel A depicts the primary efficacy outcome in the total population. The Mann–Whitney estimator, or the
probability that the treatment group had a better outcome on the composite primary endpoint, was 0.54 (95% CI 0.47–0.61), P = 0.27 (a value > 0.5
favours the active treatment). The corresponding Mann–Whitney odds was 1.17 (95% 0.89–1.55). Panel B depicts the primary efficacy outcome in
the subgroup of patients with LVEDV 200–370 mL. The Mann–Whitney estimator, or the probability that the treatment group had a better outcome
on the composite primary endpoint, was 0.61 (95% CI 0.52–0.70), P = 0.015 (a value > 0.5 favours the active treatment). The corresponding Mann–
Whitney odds was 1.57 (95% 1.09–2.35).
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respectively (P < 0.001). At Week 39, hs-cTnT levels were compar-
able: the median change was 0.001 mg/L in both groups, treatment
ratio 1.014, 95% CI 0.901–1.142.
Adjudicated clinical endpoints and investigator-reported adverse
events through Week 39 according to the actual treatment received
(i.e. the 19 patients randomized to active who received a sham pro-
cedure are included in the sham group) are shown in Table 3. Similar
proportions of patients died who underwent the active treatment and
sham procedure (HR 1.02, 95% CI 0.45–2.29). The adjudicated causes
of death were similar, although sudden cardiac death occurred in no
patient in the cardiopoietic cell treatment group and in 4 patients who
underwent the sham procedure. Aborted or sudden cardiac death
occurred in 1 (0.9% [Kaplan–Meier estimated risk]) cardiopoietic cell
treatment patient and 9 (5.4%) of sham control patients (HR 0.16,
95% CI 0.02–1.23, P = 0.04). One patient who received active
................................................................................
...............................................................................
................................................................................ ...............................................................................
....................................................................................................................................................................................................................
Table 2 Components of the primary efficacy endpoint in the total cohort and subpopulation with elevated left ven-
tricular end-diastolic volume
Total cohort Patients with baseline left
ventricular end-diastolic volume 200–370 mL
n5 271 n5 162
Cardiopoietic
cell treatment
n5 120
Sham
control
n5 151
HR or
M-W odds
(95% CI)
P-value Cardiopoietic
cell treatment
n5 66
Sham
control
n5 96
HR or
M-W odds
(95% CI)
P-value
All-cause mortality through
Week 39 (Kaplan–Meier %)
11 (9.2) 12 (7.9) 1.18 (0.52, 2.67) .70 3 (4.5) 6 (6.2) 0.73 (0.18, 2.93) 0.66
Worsening heart failure events
0 100 (83.3) 128 (84.8) 58 (87.9) 79 (82.3)
1 11 (9.2) 14 (9.3) 1.03 (0.87, 1.23) .72 4 (6.1) 9 (9.4) 0.90 (0.71, 1.12) 0.34
>_2 9 (7.5) 9 (6) 4 (6.1) 8 (8.3)
Change in MLHFQ total
score from baseline
an = 108 an = 136 an = 63 an = 89
>_10-point improvement
(decrease)
64 (59.3) 66 (48.5) 43 (68.3) 44 (49.4)
No meaningful change 37 (34.3) 60 (44.1) 0.84 (0.68, 1.04) .12 15 (23.8) 39 (43.8) 0.74 (0.55, 0.99) 0.04
>_10-point deterioration
(increase)
7 (6.5) 10 (7.4) 5 (7.9) 6 (6.7)
Change in 6-min walk distance
from baseline
an = 108 an = 131 an = 63 an = 85
>_40 m improvement
(increase)
50 (46.3) 40 (30.5) 27 (42.9) 21 (24.7)
No meaningful change 39 (36.1) 69 (52.7) 0.82 (0.66, 1.02) .07 25 (39.7) 51 (60) 0.79 (0.59, 1.06) 0.12
>_40 m deterioration
(decrease)
19 (17.6) 22 (16.8) 11 (17.5) 13 (15.3)
Change in LVESV from
baseline
an = 102 an = 124 an = 63 an = 85
>_15 mL improvement
(decrease)
51 (50) 56 (45.2) 36 (57.1) 41 (48.2)
No meaningful change 33 (32.4) 36 (29) 0.89 (0.73, 1.09) .26 18 (28.6) 23 (27.1) 0.81 (0.60, 1.09) 0.17
>_15 mL deterioration
(increase)
18 (17.6) 32 (25.8) 9 (14.3) 21 (24.7)
Change in LVEF from
baseline
an = 102 an = 124 an = 63 an = 85
>_4% absolute improvement
(increase)
69 (67.6) 82 (66.1) 42 (66.7) 56 (65.9)
No meaningful change 28 (27.5) 33 (26.6) 0.97 (0.81, 1.15) .73 19 (30.2) 22 (25.9) 0.96 (0.74, 1.25) .76
>_4% absolute
deterioration (decrease)
5 (4.9) 9 (7.3) 2 (3.2) 7 (8.2)
Data are expressed as number (percent). Hazard ratio (HR) for active treatment vs. control is provided for mortality. The Mann–Whitney (M-W) odds for worse outcome in
active vs. control is given for ordered categories. Values <1.0 favour active treatment.
LVEF, left ventricular ejection fraction; LVESV, left ventricular end-systolic volume; MLHFQ, Minnesota Living with Heart Failure Questionnaire.
an reflects the number of patients with data.
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treatment had a cardiac transplantation. Occurrence of other adjudi-
cated clinical endpoints including myocardial infarction and stroke
were similar in the groups (Table 3). Similar hospitalization rates after
the index procedure were observed through Week 39 (26.2% for ac-
tive treatment vs. 27.4% for control, HR 1.01, 95% CI 0.64–1.59, P =
0.96), most often due to heart failure (15.2% for active and 18.1% for
control) (eTable 2 in Supplementary material online, Section 3.2).
Discussion
The CHART-1 study is the largest cardiovascular regenerative medi-
cine trial to date addressing the effect of cardiopoiesis-based cell ther-
apy in ischaemic heart failure patients with moderate to severe
symptoms. In this at-risk population with limited therapeutic options,
the trial was neutral regarding the primary endpoint, a hierarchical
composite encompassing all-cause mortality, worsening heart failure
events, MLHFQ score, 6-min walk distance, LVESV and LVEF assessed
at 39 weeks. Exploration of the primary composite endpoint accord-
ing to baseline heart failure severity revealed a clinically relevant popu-
lation that appeared to benefit from cardiopoietic cell therapy. This
sizable target population, representing 60% of the whole study cohort,
was characterized by severe heart enlargement (baseline LVEDV
200–370 mL). These patients had greater improvement in 6-min walk
distance consistent with favourable effects on myocardial structure
(i.e. LVESV). Directionally similar treatment effects on all-cause mor-
tality and worsening heart failure events were also observed in this
subset. Patients displaying a lower (< 200 mL) or greater (> 370 mL)
LVEDV did not appear to respond to cell therapy in this study. These
data suggest that targeted patient selection using disease severity
markers should be considered for future clinical trials and/or potential
clinical application of cell therapy in patients with heart failure. Indeed,
a call for a focus on precision medicine has been issued, where clinical
studies would target well-defined patient populations to improve de-
velopment of effective cardiovascular treatments.21
The CHART-1 study corroborates, in a larger heart failure cohort,
the feasibility, safety and initial efficacy signals detected in the C-CURE
trial.16 Clinical surveillance documented safety through 39 weeks
without excess adverse events attributable to cardiopoietic cell ther-
apy. Peri-procedural events in the CHART-1 trial were consistent
with well-established complications of left heart catheterization and/
or intramyocardial injection, which can spike with the introduction of
a new device but generally recede as interventional experience and
procedural volume accrue.22 Notably, a significantly lower incidence
of sudden or aborted sudden deaths was documented in cardiopoietic
cell-treated patients compared to controls, underpinning clinical safety
across both C-CURE16 and CHART-1 trials.
Heart failure clinical trial experience points to inter-trial and inter-
patient variability in cell therapy outcomes.23–25 Recognizing that only
a limited number of patients with ischaemic heart disease harbors rep-
arative stem cells, processes have been introduced to optimize rep-
arative outcome.26 The ixCELL-DCM trial is a recent example where
a reduction in adjudicated clinical cardiac events in ischaemic cardio-
myopathy was documented after delivery of an expanded multicellular
product.13 Leveraging the cardiopoiesis platform in conjunction with a
novel catheter fitted with a curved needle delivery system,15 the
CHART-1 clinical experience advances current knowledge by iden-
tifying disease severity as a potential modifier of cell therapy benefit.
In this regards, heart failure is a progressive and heterogeneous
syndrome where conventional symptoms or ejection fraction often
fail to identify patients that optimally respond to a therapy. Non-
uniform responses in advanced heart failure have been reported in a
spectrum of therapies including revascularization,27 interventions tar-
geting functional mitral regurgitation28 or CRT.29 Of note and con-
sistent with the CHART-1 findings, the degree of baseline LV
enlargement has previously been detected as a modifying factor influ-
encing therapeutic responsiveness to patients undergoing CRT,
where the response was most robust in patients with LV end-
diastolic volume index >125 ml/m2.29 The relationship between left
ventricular volumes and clinical outcomes in heart failure is well rec-
ognized.3 The CHART-1 study extends these findings by defining a
range of LVEDV that appeared to segregate heart failure patients
with the highest potential to benefit from cell-based therapy.
Evidence from the CHART-1 experience, in the context of prior
knowledge with other therapies27–29 and recent proposals to stream-
line clinical development,21 suggests that heart failure management
should be patient-tailored based on disease severity markers, such as
degree of left ventricular dilation.
The present data should be interpreted in the context of the fol-
lowing limitations. Use of a composite primary endpoint was in-
tended to increase the statistical precision of the trial, yet if an
important component of the composite outcome is not substantially
modified by the treatment then the statistical power to detect effects
on the overall composite may be reduced.30 Indeed, neutrality in the
primary hierarchical composite endpoint within the overall study
population was related primarily to a neutral effect on all-cause mor-
tality or worsening heart failure. This finding may reflect the 39-week
Figure 3 Primary efficacy outcome by markers of disease sever-
ity. This figure shows the Mann–Whitney estimator, or the probabil-
ity that the treatment group had a better outcome on the
composite primary endpoint, for patients above and below the me-
dian values for LVEDV, LVESV, MLHFQ score, and 6-min walk dis-
tance, and for LVEF above and below a cutpoint of 30%.
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time point for the primary outcome. In this context, longer follow-up
is planned to evaluate the effect of cardiopoietic cell therapy.
Eighteen patients initially randomized to the cardiopoietic cell group
did not meet cardiopoietic cell release criteria and the procedure
was contraindicated in one patient; these patients received a sham
procedure and were not included in the primary efficacy analysis.
This approach assesses the effect of cardiopoietic cells in those pa-
tients who actually received them. The result of an analysis in a modi-
fied intent-to-treat set, which included the process failures who
underwent a sham procedure in the active group for analysis, was
nearly identical (Mann–Whitney estimator 0.54, P= 0.283) to that of
the primary endpoint (Mann–Whitney estimator 0.54, P= 0.27).
STEPP was used to identify the influence of LVEDV on the primary
endpoint. This approach is methodologically preferred compared to
conventional post-hoc analysis, as STEPP constructs overlapping sub-
populations along the continuum of the covariate, improving the pre-
cision of the estimated treatment effects.31 LV volumes and function
were assessed by transthoracic echocardiography using established
guidelines.18 To minimize reproducibility issues, measurements were
performed by a trained single echocardiographer per center with
central core analyses. Although inadequate bone marrow aspiration
or suboptimal outcome of the production process preventing cell
product release occurred, these are expected to diminish as the
technology and procedural experience matures. Finally, the study
population was Caucasian and predominantly male. The present find-
ings should be confirmed in subsequent studies with broader repre-
sentation of women and non-Caucasian racial groups.
Conclusions
The CHART-1 study is the largest cardiovascular regenerative medi-
cine clinical trial to date that addresses the efficacy and safety of
cardiopoiesis-based cell therapy in ischaemic heart failure. The trial
Figure 4 Subpopulation treatment effect pattern plot by markers of disease severity. Subpopulation Treatment Effect Pattern Plots (STEPPs) were
used to further evaluate the potential effect of treatment according to baseline markers of disease severity. This figure shows the STEPP results ac-
cording to baseline MLHFQ score (panel A), baseline LVEDV (panel B), baseline 6-min walk distance (panel C), and baseline LVESV (panel D).
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was neutral regarding the primary endpoint. Using markers of heart
failure severity, the CHART-1 trial identified a clinically relevant pa-
tient population characterized by severe heart enlargement (LVEDV
200–370 mL) that appeared to derive consistent benefit from cardio-
poietic cell treatment as regards the primary endpoint. Insights from
the CHART-1 trial, namely targeting the patient population using in-
dices of disease severity, should be considered for cardiopoietic cell
therapy in future clinical trials. This application of the CHART-1 re-
sults could be an effective step towards cell-based precision medicine
in patients with advanced ischaemic heart failure.32
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Table 3 Mortality and cardiovascular events and
adverse events through 39 weeksa
Cardiopoietic
cell treatment
Sham control
n5 120 n 5 170b
Total deathsc 10 (8.3) 14 (8.2)
During hospitalization for study procedure
Cardiovascular – other CV cause 1 (0.8) 0
After hospitalization for study procedure
Cardiovascular death 9 (7.6) 12 (7.1)
Heart failure/cardiogenic shock 6 (5.0) 7 (4.2)
Sudden cardiac death 0 4 (2.4)
Acute MI 1 (0.9) 0
Stroke 1 (0.9) 0
Undetermined cause 1 (0.9) 1 (0.6)
Non-cardiovascular death 0 2 (1.2)
Infection 0 2 (1.2)
Non-fatal events
Cardiac transplantation 1 (0.9) 0
Myocardial infarction
During hospitalization for study 0 0
After hospitalization for study 1 (0.9) 1 (0.6)
Stroke
During hospitalization for study 1 (0.8) 0
After hospitalization for study 2 (1.8) 2 (1.2)
Aborted sudden cardiac death
During hospitalization for study 0 0
After hospitalization for study 1 (0.9) 5 (3.0)
Adverse Events Reported by interventional investigators (not blinded)
Any AE 25 (20.8) 9 (5.3)
AE related to cardiopoeitic cells
or sham as reported by investigator
10 (8.3) 2 (1.2)
AE related to the catheter as
reported by investigator
12 (10) 1 (0.6)
Any serious AE 17 (14.1) 3 (1.8)
Serious AE with fatal outcome 2 (1.7) 0
Adverse Events Reported by evaluator investigators (blinded)
Any AE 62 (52.5) 90 (53.0)
AE related to cardiopoietic cells
or sham as reported by investigator
5 (4.2) 2 (1.2)
AE related to the catheter as
reported by investigator
4 (3.4) 2 (1.2)
Any serious AE 44 (37.2) 63 (37.1)
Serious AE with fatal outcome 8 (6.8) 17 (10)
Data are expressed as number (percent).
AE, adverse event; CV, cardiovascular; MI, myocardial infarction.
aKaplan–Meier %.
bSafety set comprised of 151 sham control and 19 patients who did not meet car-
diopoietic cell release specifications or had a contraindication but underwent
sham procedure.
cNote the number of deaths shown in Figure 1 is different from the values shown
in this table, because Figure 1 includes 4 deaths (1 in patients randomized to and
treated with active, 2 randomized to and treated with sham, and 1 randomized to
active and treated with sham) who died after day 273 but before a Week 39 visit
could be performed. Thus, they are included in the patient disposition figure
based on visit completion, but they are not included in calculation of Week 39
(or day 273) event rates. There were a total of 24 deaths by day 273: 10 in pa-
tients randomized to and treated with active, 11 randomized to and treated with
sham, and 3 randomized to active and treated with sham. There were 2 additional
patients who had an urgent LVAD placed, but who did not die by day 273: 1 pa-
tient randomized to and treated with active, and 1 patient randomized to and
treated with sham. These urgent LVAD placements were considered deaths in
the efficacy analyses.
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